| Description | 5,6-dihydro-5-Fluorouracil (5-FUH2) is an inactive metabolite of 5-FU and can be used for the study of organismal metabolism. |
| In vitro | 5,6-dihydro-5-Fluorouracil （5-Fu）与NSC 123127（Dox）的结合显示出协同的抗癌效应。针对人类乳腺癌（MDA-MB-231）细胞，5-Fu/Dox-DNM的IC50值为0.25 μg/mL，其中Dox-DNM和5-Fu-DNM的细胞毒性分别增加了11.2倍和6.1倍[4]。在使用5,6-dihydro-5-Fluorouracil （5-FU）和CDDP处理的NFBD1抑制的NPC细胞中，通过慢病毒介导的短发夹RNA敲减NFBD1表达的NPC CNE1细胞系提高了敏感性。在用CDDP或5,6-dihydro-5-Fluorouracil 治疗的CNE1细胞中，NFBD1的敲除显著诱导了凋亡[2]。 |
| In vivo | 以每周三次，每次23 mg/kg的剂量持续给予14天，5,6-dihydro-5-Fluorouracil(5-FU)从治疗第三天开始诱导与急性肠炎相关的胃肠传输加速。这可能导致肠神经系统(ENS)在第7天之后观察到的持续性变化，而14天的治疗结果则是胃肠传输延迟和结肠运动障碍[1]。 |
| Target activity | MDA-MB-231 cells:0.25 μg/mL |
| Synonyms | 5-fluorodihydrouracil, 5-Fluoro-dihydro-pyrimidine-2,4-dione |
| molecular weight | 132.09 |
| Molecular formula | C4H5FN2O2 |
| CAS | 696-06-0 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 43 mg/mL (325.53 mM), Sonication is recommended. PBS (pH 7.2): 8 mg/mL Ethanol: 0.8 mg/mL DMF: 60 mg/mL |
| References | 1. McQuade RM, et al. Gastrointestinal dysfunction and enteric neurotoxicity following treatment with anticancer chemotherapeutic agent 5-fluorouracil. Neurogastroenterol Motil. 2016 Jun 28. 2. Zeng Q, et al. Knockdown of NFBD1/MDC1 enhances chemosensitivity to NSC 119875 or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells. Mol Cell Biochem. 2016 Jul;418(1-2):137-46. 3. Jones DH, et al. Ten-Year and Beyond Follow-up After Treatment With Highly Purified Liquid-Injectable Silicone for HIV-Associated Facial Lipoatrophy: A Report of 164 Patients. Dermatol Surg. 2019 Jul;45(7):941-948. 4. Han R, et al. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and NSC 123127 for enhanced therapeutic efficacy. J Drug Target. 2016 Jun 29:1-28. |